BioSpace News Archive

Submission follows completion of a Clinical Endpoint study

Recipharm announced today ongoing large-scale commercial manufacturing of RedHill Biopharma’s (Nasdaq: RDHL) drug, Talicia® (omeprazole magnesium, amoxicillin and rifabutin) delayed-release capsules 10 mg[1]/250 mg/12.5 mg, for its planned launch in the first quarter 2020.

In 2018, almost 12,000 Canadian children and youth age 17 and younger were readmitted to hospital within 30 days of their initial hospitalization.

Funds will advance development of ViGeneron’s next-generation ophthalmic gene therapy pipeline and vector platforms

Technavio has announced its latest market research report titled global healthcare logistics market 2019-2023.

Ridgeback Biotherapeutics LP, a closely held biotechnology company, announced that the results for the Pamoja Tulinde Maisha clinical trial have been published in the New England Journal of Medicine.

Liminal BioSciences Inc. acknowledges the press release issued by the Autorité des Marchés Financiers in which the AMF announced that after a thorough investigation, the AMF has determined that no violation or breach of securities regulation occurred in connection with the refinancing transactions completed by the Company in April 2019.

Ascletis Pharma Inc. announces that Ascletis XinNuo Medicine Co.,Ltd., a wholly-owned subsidiary of Ascletis, has recently obtained the Pharmaceutical Trade License and GSP Certificate issued by ZheJiang Medical Products Administration.

Satralizumab added to baseline immunosuppressant therapy significantly reduced risk of relapse in patients with neuromyelitis optica spectrum disorder (NMOSD).

International medical imaging IT and cybersecurity company Sectra has signed a five-year contract to install its radiology imaging solution at Maastricht University Medical Center in the Netherlands.